Methotrexate and emerging therapies

J.M. Kremer

Joel M. Kremer, MD, Professor of Medicine, Head, Division of Rheumatology, Department of Medicine, Division of Rheumatology, Mail Code 100, The Albany Medical College, 47 New Scotland Avenue, Albany, New York 12208-3479, USA.

ABSTRACT
More publications in the medical literature have described the clinical efficacy and toxicity of methotrexate (MTX) than of any other drug ever used for rheumatic diseases. A knowledgeable clinican can thus rely on evidence-based medicine to guide the use of this agent. Because MTX is not remission-inducing, many new therapies are being combined with it in order to achieve a greater therapeutic response. This trend will likely continue and expand as more novel agents are introduced.

Key words
Methotrexate, rheumatoid arthritis, combination therapy.

Clin Exp Rheumatol 1999; 17 (Suppl. 18): S43 - S46.